Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.61 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.61 |
| ▸ | KDR | P35968 | 3/20 | 0.61 |
| ▸ | HDAC8 | Q9BY41 | 5/20 | 0.55 |
| ▸ | HDAC6 | Q9UBN7 | 5/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.55 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | PDE5A | O76074 | 2/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.45 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2257197 | 0.84 | EGFR (0.67) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL2257482 | 0.81 | EGFR (0.60) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL3114136 | 0.81 | EGFR (0.60) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL19789164 | 0.81 | EGFR (0.74) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL3115859 | 0.81 | EGFR (0.74) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL2263168 | 0.80 | EGFR (0.58) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL2257678 | 0.79 | EGFR (0.64) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL3109895 | 0.78 | EGFR (0.70) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL2256177 | 0.78 | EGFR (0.70) | EGFRPDGFRBKDRHDAC8HDAC6 | |
| SCHEMBL3120940 | 0.78 | EGFR (0.70) | EGFRPDGFRBKDRHDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | claimed |
| EP-1833482-A2 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2007-09-19 | — | — | EP | claimed |
| WO-2006074147-A2 | NITROGEN CONTAINING BICYCLIC COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2006-07-13 | — | — | WO | claimed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-7989462-B2 | 4-arylamin-or-4-heteroarylamino-quinazolines and analogs as activators of caspases and inducers of apoptosis and the use thereof | MYREXIS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | MYRIAD GENETICS, INC. (US) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004297-A1 | COMPOUNDS AND THERAPEUTICAL USE THEREOF | BAD, CASP3, BAX | EGFR 2915/4885PDGFRB 2620/4885KDR 3716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.